Trials / Not Yet Recruiting
Not Yet RecruitingNCT06081595
Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment
Fluzoparib Combined With Apatinib for Maintenance Treatment in Platinum-Sensitive Relapsed Ovarian Carcinoma: A Phase II Single-arm, Open Label, Multicenter Trial
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 54 (estimated)
- Sponsor
- Jin Li · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is a Phase II single-arm, open label, multicenter study to access the effects and tolerability of fluzoparib combined with apatinib for maintenance treatment in platinum-sensitive relapsed ovarian carcinoma .
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fluzoparib | Fluzoparib 100mg bid |
| DRUG | Apatinib | Apatinib 375mg qd |
Timeline
- Start date
- 2023-10-30
- Primary completion
- 2024-12-30
- Completion
- 2026-12-30
- First posted
- 2023-10-13
- Last updated
- 2023-10-13
Source: ClinicalTrials.gov record NCT06081595. Inclusion in this directory is not an endorsement.